Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
Open Access
- 14 November 2019
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-19
Abstract
BRAF and MEK1/2 inhibitors are effective in melanoma but resistance inevitably develops. Despite increasing the abundance of pro-apoptotic BIM and BMF, ERK1/2 pathway inhibition is predominantly cytostatic, reflecting residual pro-survival BCL2 family activity. Here, we show that uniquely low BCL-XL expression in melanoma biases the pro-survival pool towards MCL1. Consequently, BRAF or MEK1/2 inhibitors are synthetic lethal with the MCL1 inhibitor AZD5991, driving profound tumour cell death that requires BAK/BAX, BIM and BMF, and inhibiting tumour growth in vivo. Combination of ERK1/2 pathway inhibitors with BCL2/BCL-w/BCL-XL inhibitors is stronger in CRC, correlating with a low MCL1:BCL-XL ratio; indeed the MCL1:BCL-XL ratio is predictive of ERK1/2 pathway inhibitor synergy with MCL1 or BCL2/BCL-w/BCL-XL inhibitors. Finally, AZD5991 delays acquired BRAFi/MEKi resistance and enhances the efficacy of an ERK1/2 inhibitor in a model of acquired BRAFi + MEKi resistance. Thus combining ERK1/2 pathway inhibitors with MCL1 antagonists in melanoma could improve therapeutic index and patient outcomes.Keywords
Funding Information
- Cancer Research UK (A14867)
- RCUK | Biotechnology and Biological Sciences Research Council (BB/J004456/1, BB/P013384/1, BBS/E/B000C0433, BBS/E/B/000C0434)
- AstraZeneca
This publication has 58 references indexed in Scilit:
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 2011
- Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on BakOncogene, 2011
- Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid CellsJournal of Biological Chemistry, 2011
- Amplification of the Driving Oncogene, KRAS or BRAF , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer CellsScience Signaling, 2011
- Stepwise Activation of BAX and BAK by tBID, BIM, and PUMA Initiates Mitochondrial ApoptosisMolecular Cell, 2009
- Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind LigandsJournal of Biological Chemistry, 2009
- Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimeticJournal of Clinical Investigation, 2008
- Structural insights into the degradation of Mcl-1 induced by BH3 domainsProceedings of the National Academy of Sciences, 2007
- FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawalJournal of Experimental Medicine, 2006